Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-PSMA monoclonal antibody-MMAE conjugate

An antibody-drug conjugate (ADC) containing a fully human monoclonal antibody directed against prostate-specific membrane antigen (PSMA), conjugated via a stable, enzyme-cleavable linker to monomethylauristatin E (MMAE), an auristatin derivative and a potent microtubule inhibitor, with potential antineoplastic activity. The monoclonal antibody moiety of this conjugate selectively binds to PSMA, a protein which is abundantly expressed on the surface of metastatic and hormone-refractory prostate cancer cells. Upon internalization and proteolytic cleavage, MMAE binds to tubulin and inhibits its polymerization, resulting in G2/M phase arrest and tumor cell apoptosis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-PSMA monoclonal antibody-monomethylauristatin E conjugate
prostate-specific membrane antigen antibody-drug conjugate
Abbreviation:anti-PSMA-MMAE-ADC
Code name:PSMA ADC
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search